# Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.

> **NCT06454968** · PHASE2 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Orelabrutinib, obinutuzumab, lenalidomide

## Key facts

- **NCT ID:** NCT06454968
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-20
- **Primary completion:** 2026-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06454968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06454968, "Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06454968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*